Q1 EPS Estimates for Haemonetics Decreased by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Investment analysts at Zacks Research decreased their Q1 2027 earnings estimates for Haemonetics in a research note issued to investors on Thursday, May 28th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $1.09 per share for the quarter, down from their previous forecast of $1.19. The consensus estimate for Haemonetics’ current full-year earnings is $5.23 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2027 earnings at $1.32 EPS, FY2027 earnings at $5.20 EPS, Q1 2028 earnings at $1.31 EPS, Q3 2028 earnings at $1.52 EPS, FY2028 earnings at $5.69 EPS and FY2029 earnings at $6.19 EPS.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The company had revenue of $346.35 million during the quarter, compared to the consensus estimate of $336.83 million. During the same quarter in the prior year, the firm posted $1.24 earnings per share. Haemonetics’s revenue for the quarter was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS.

HAE has been the subject of several other research reports. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $72.00 to $80.00 in a research note on Friday, May 22nd. BTIG Research reiterated a “buy” rating and set a $88.00 target price on shares of Haemonetics in a research note on Friday, February 6th. JPMorgan Chase & Co. decreased their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Mizuho decreased their target price on shares of Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Finally, Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $77.11.

Haemonetics Price Performance

Shares of HAE opened at $68.02 on Monday. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of 33.67, a price-to-earnings-growth ratio of 1.36 and a beta of 0.55. The firm has a 50-day simple moving average of $58.95 and a 200-day simple moving average of $67.40. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in HAE. Kemnay Advisory Services Inc. purchased a new position in Haemonetics during the fourth quarter worth about $26,000. True Wealth Design LLC increased its holdings in Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 335 shares in the last quarter. Leonteq Securities AG purchased a new position in Haemonetics in the fourth quarter valued at about $30,000. EverSource Wealth Advisors LLC increased its holdings in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in Haemonetics in the fourth quarter valued at about $34,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.